Short answer: It often does. Insulin labels list weight gain as a common effect and put it down to insulin's building-up (anabolic) action and to less sugar being lost in urine. In trials, people on Tresiba gained an average of 1.8 kg with type 1 diabetes and 3.0 kg with type 2 over a year. In UKPDS, people assigned insulin gained about 4.0 kg, more than with the sulfonylureas tested.
The Lantus label (section 6.1) says weight gain "has occurred with insulin including LANTUS and has been attributed to the anabolic effects of insulin and the decrease in glucosuria." Glucosuria is sugar spilling into the urine when blood sugar is high. When insulin brings blood sugar down, those calories stay in the body instead of being lost.
The Tresiba label (section 6.1) gives the same anabolic explanation. Both list weight gain alongside low blood sugar, injection site reactions and swelling (edema) as common adverse reactions.
| Study | Who | Weight change |
|---|---|---|
| Tresiba clinical program (52 weeks) | Type 1 diabetes | +1.8 kg |
| Tresiba clinical program (52 weeks) | Type 2 diabetes | +3.0 kg |
| ORIGIN (Lantus label, median 6.2 years) | Adults 50+ with early type 2 diabetes or raised glucose, plus heart disease or risk factors | 2.2 kg more than standard care |
| UKPDS 33 (10 years) | Newly diagnosed type 2, insulin arm | +4.0 kg |
| UKPDS 33 (10 years) | Chlorpropamide or glibenclamide arms | +2.6 kg and +1.7 kg |
In UKPDS, the whole intensive group gained 2.9 kg on average, significantly more than the diet-based conventional group. These are averages: some people gained more, some less, and the trials do not predict one person's result.
Low blood sugar plays a part in daily life too: treating lows means eating fast-acting sugar, and the labels warn that changes in meals, activity and other medicines change insulin needs. The Lantus label also warns that pairing insulin with pioglitazone or rosiglitazone can cause fluid retention and heart failure, which shows up as sudden weight gain or swelling and is a reason to call the prescriber.
Other diabetes medicines push the other way. Metformin, SGLT2 medicines and GLP-1 medicines are linked to weight loss or no gain; see does metformin cause weight loss and SGLT2 medicines and weight loss. Which combination fits is a prescriber decision.
Weight on insulin is easier to discuss with numbers. Dose Track can log weight next to insulin doses and lows, so the care team sees whether a change lines up with a new dose, more lows or a new medicine. Sudden gain with swelling or shortness of breath is different from slow drift, and the Lantus patient information lists it among signs of heart failure to report.
Read more on Dose Track: Lantus side effects · Basal insulin · Track weight in Dose Track